SGLT2 inhibitors – An insulin-independent therapeutic approach for treatment of type 2 diabetes: Focus on canagliflozin

Diabetes, Metabolic Syndrome and Obesity

Volumn 8, Issue , 2015, Pages 543-554

  Seufert, Jochen ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Canagliflozin; Dapagliflozin; Empagliflozin; Sodium glucose cotransporter 2 (SGLT2) inhibitor; Type 2 diabetes

Indexed keywords

CANAGLIFLOZIN; DAPAGLIFLOZIN; EMPAGLIFLOZIN; GLIMEPIRIDE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PIOGLITAZONE; SITAGLIPTIN; SODIUM GLUCOSE COTRANSPORTER 1; SODIUM GLUCOSE COTRANSPORTER 2; SULFONYLUREA; TRIACYLGLYCEROL;

ALBUMINURIA; BALANITIS; BALANOPOSTHITIS; BODY FAT; BODY MASS; BODY WEIGHT; CARBOHYDRATE INTOLERANCE; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; CONSTIPATION; DIABETIC NEPHROPATHY; DIASTOLIC BLOOD PRESSURE; DIETARY INTAKE; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; DUAL ENERGY X RAY ABSORPTIOMETRY; ENZYME INHIBITION; EXERCISE; GLOMERULUS FILTRATION RATE; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSURIA; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOGLYCEMIA; IN VITRO STUDY; INCIDENCE; INSULIN RELEASE; INSULIN SENSITIVITY; INTRAABDOMINAL FAT; KIDNEY PROXIMAL TUBULE; MACROALBUMINURIA; METABOLIC DISORDER; MORBIDITY; MORTALITY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; ORTHOSTATIC HYPOTENSION; PANCREAS ISLET BETA CELL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POLYDIPSIA; POSITIONAL DIZZINESS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; RENAL PROTECTION; REVIEW; RISK FACTOR; SODIUM EXCRETION; SUBCUTANEOUS FAT; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; URINARY FREQUENCY; URINARY TRACT INFECTION; VAGINA CANDIDIASIS; VAGINAL PRURITUS; VULVOVAGINAL PRURITUS; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 84946821069     PISSN: None     EISSN: 11787007     Source Type: Journal    
DOI: 10.2147/DMSO.S90662     Document Type: Review

References (50)

1. Inzucchi SE, Bergenstal RM, Buse JB, etal. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015; 38(1): 140-149.
2. de Pablos-Velasco P, Parhofer KG, Bradley C, etal. Current level of glycaemic control and its associated factors in patients with type 2 diabetes across Europe: data from the PANORAMA study. Clin Endocrinol (Oxf). 2014; 80(1): 47-56.
3. Fonseca VA. Defining and characterizing the progression of type 2 diabetes. Diabetes Care. 2009; 32(Suppl 2): S151-S156.
4. Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Therapie des Typ-2-Diabetes-Langfassung, 1. Auflage. Version 3. 2013, zuletzt geändert: April 2014. [National Patient-Centered Guideline: Therapy of Type 2 Diabetes-Long Version, 1. Edition, Version 3. 2013, latest adaptation: April 2014]. DOI: 10.6101/AZQ/000203. Available from: http: //www.versorgungsleitlinien.de/themen/diabetes2/dm2_therapie. Accessed November 19, 2014. German.
5. Sarwar N, Gao P, Seshasai SR, etal. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010; 375(9733): 2215-2222.
6. Hauner H, Hanisch J, Bramlage P, etal. Prevalence of undiagnosed type-2-diabetes mellitus and impaired fasting glucose in German primary care: data from the German Metabolic and Cardiovascular Risk Project (GEMCAS). Exp Clin Endocrinol Diabetes. 2008; 116(1): 18-25.
7. Berthold HK, Gouni-Berthold I, Bestehorn K, etal. Kardiovaskuläre Risikofaktoren bei Typ-2-Diabetikern in Deutschland-ein Versorgungsparadox. [Cardiovascular Risk Factors in Patients With Type 2 Diabetes in Germany]. Dtsch Arztebl. 2007; 104(A): 861-867. German.
8. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998; 352(9131): 854-865.
9. Dormandy JA, Charbonnel B, Eckland DJ, etal. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005; 366(9493): 1279-1289.
10. Scirica BM, Bhatt DL, Braunwald E, etal. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013; 369(14): 1317-1326.
11. White WB, Cannon CP, Heller SR, etal. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013; 369(14): 1327-1335.
12. Bays H. From victim to ally: the kidney as an emerging target for the treatment of diabetes mellitus. Curr Med Res Opin. 2009; 25(3): 671-681.
13. Rahmoune H, Thompson PW, Ward JM, Smith CD, Hong G, Brown J. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes. 2005; 54(12): 3427-3434.
14. INVOKANA™ (canagliflozin) tablets, for oral use [summary of product characteristics]. Beerse, Belgium: Janssen-Cilag International NV; 2015.
15. Sha S, Polidori D, Farrell K, etal. Pharmacodynamic differences between canagliflozin and dapagliflozin: results of a randomized, double-blind, crossover study. Diabetes Obes Metab. 2015; 17(2): 188-197.
16. Polidori D, Sha S, Mudaliar S, etal. Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study. Diabetes Care. 2013; 36(8): 2154-2161.
17. Ferrannini E, Muscelli E, Frascerra S, etal. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest. 2014; 124(2): 499-508.
18. Liang Y, Arakawa K, Ueta K, etal. Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models. PLoS One. 2012; 7(2): e30555.
19. Sha S, Devineni D, Ghosh A, etal. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes Metab. 2011; 13(7): 669-672.
20. Nomura S, Sakamaki S, Hongu M, etal. Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus. J Med Chem. 2010; 53(17): 6355-6360.
21. Seufert J. SGLT-2 inhibition with canagliflozin: a new option for the treatment of type 2 diabetes. Dtsch Med Wochenschr. 2014; 139(Suppl 2): S52-S58.
22. Ehrenkranz JR, Lewis NG, Kahn CR, Roth J. Phlorizin: a review. Diabetes Metab Res Rev. 2005; 21(1): 31-38.
23. FORXIGA™ (dapagliflozin) 5 mg and 10 mg film-coated tablets [summary of product characteristics]. Middlesex, UK: Bristol-Myers Squibb/AstraZeneca EEIG; 2014.
24. JARDIANCE™ (empagliflozin) 10 mg film-coated tablets [summary of product characteristics]. Ingelheim, Germany: Boehringer Ingelheim GmbH; 2014.
25. Neal B, Perkovic V, de Zeeuw D, etal. Rationale, design, and baseline characteristics of the canagliflozin cardiovascular assessment study (CANVAS)—a randomized placebo-controlled trial. Am Heart J. 2013; 166(2): 217-223.
26. Bode B, Stenlöf K, Sullivan D, Fung A, Usiskin K. Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial. Hosp Pract (1995). 2013; 41(2): 72-84.
27. Leiter LA, Yoon KH, Arias P, etal. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, Phase 3 study. Diabetes Care. 2015; 38(3): 355-364.
28. Cefalu WT, Leiter LA, Yoon KH, etal. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet. 2013; 382(9896): 941-950.
29. Forst T, Guthrie R, Goldenberg R, etal. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone. Diabetes Obes Metab. 2014; 16(5): 467-477.
30. Lavalle-González FJ, Januszewicz A, Davidson J, etal. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia. 2013; 56(12): 2582-2592.
31. Neal B, Perkovic V, de Zeeuw D, etal. Efficacy and safety of canagliflozin, an inhibitor of sodium glucose co-transporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes. Diabetes Care. 2015; 38(3): 403-411.
32. Schernthaner G, Gross JL, Rosenstock J, etal. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week, randomized trial. Diabetes Care. 2013; 36(9): 2508-2515.
33. Stenlöf K, Cefalu WT, Kim KA, etal. Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study. Curr Med Res Opin. 2014; 30(2): 163-175.
34. Stenlöf K, Cefalu WT, Kim KA, etal. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab. 2013; 15(4): 372-382.
35. Bode B, Stenlöf K, Harris S, etal. Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55 to 80 years with type 2 diabetes. Diabetes Obes Metab. 2015; 17(3): 294-303.
36. Gilbert RE, Weir MR, Fioretto P, Law G, Usiskin K, Meninger G. Effect of canagliflozin (CANA) in patients with type 2 diabetes mellitus (T2DM) based on age and estimated glomerular filtration rate (eGFR) [abstract]. Diabetes. 2014; (Suppl 1): A212-A343. Abstract 1034-P.
37. Basile JN. The potential of sodium glucose cotransporter 2 (SGLT2) inhibitors to reduce cardiovascular risk in patients with type 2 diabetes (T2DM). J Diabetes Complications. 2013; 27(3): 280-286.
38. Neal B, Matthews D, Fulcher G, etal. 52-week effects of canagliflozin, an inhibitor of sodium glucose co-transporter 2 (SGLT2), added to insulin therapy in type 2 diabetes (T2D). Poster presented at: 22nd Biennial World Diabetes Congress of the International Diabetes Federation (IDF); December 2-6, 2013; Melbourne, Australia.
39. Ferrannini E, Cushman WC. Diabetes and hypertension: the bad companions. Lancet. 2012; 380(9841): 601-610.
40. Matthaei S. Canagliflozin monotherapy: clinical study data in type 2 diabetes mellitus. Dtsch Med Wochenschr. 2014; 139(Suppl 2): S59-S64.
41. Wilke T, Ahrendt P, Schwartz D, Linder R, Ahrens S, Verheyen F. Incidence and prevalence of type 2 diabetes mellitus in Germany: an analysis based on 5.43 million patients. Dtsch Med Wochenschr. 2013; 138(3): 69-75.
42. Weir M, Januszewicz A, Gilbert R, etal. Effect of canagliflozin on blood pressure and adverse events related to osmotic diuresis and reduced intravascular volume in patients with type 2 diabetes mellitus. J Clin Hypertens (Greenwich). 2014; 16(12): 875-882.
43. Usiskin K, Kline I, Fung A, Mayer C, Meininger G. Safety and tolerability of canagliflozin in patients with type 2 diabetes: pooled analysis of phase 3 study results. Postgrad Med. 2014; 126(3): 16-34.
44. Weidmann P, de Courten M, Ferrari P. Effect of diuretics on the plasma lipid profile. Eur Heart J. 1992; 13(Suppl G): 61-67.
45. Plosker GL. Canagliflozin: a review of its use in patients with type 2 diabetes mellitus. Drugs. 2014; 74(7): 807-824.
46. Committee for Medicinal Products for Human Use (CHMP). Assessment Report Canagliflozin. EMA/374133/2013; September 19, 2013. Available from: http: //www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002649/WC500156457.pdf. Accessed November 19, 2014.
47. Amir J, Waite M, Tobler J, etal. The role of hyperglycemia in mechanisms of exacerbated inflammatory responses within the oral cavity. Cell Immunol. 2011; 272(1): 45-52.
48. Nicolle LE, Capuano G, Fung A, Usiskin K. Urinary tract infection in randomized phase III studies of canagliflozin, a sodium glucose co-transporter 2 inhibitor. Postgrad Med. 2014; 126(1): 7-17.
49. Nyirjesy P, Sobel JD, Fung A, etal. Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. Curr Med Res Opin. 2014; 30(6): 1109-1119.
50. Mikhail N. Safety of canagliflozin in patients with type 2 diabetes. Curr Drug Saf. 2014; 9(2): 127-132.